Data Sheet (Cat.No.TMPY-03859)

TargetMol

DHRS9 Protein, Human, Recombinant (His)

General Information

Synonyms:	3α-HSD;RDHTBE;3ALPHA-HSD;RDH-E2;RETSDR8;dehydrogenase/reductase (SDR family) member 9;3-alpha-HSD;SDR9C4;RDH15;RDH-TBE;RDHL;3-α-HSD
Protein Construction:	A DNA sequence encoding the human DHRS9 (NP_005762.2) (Arg18-Val319) was expressed with a polyhistidine tag at the N-terminus. Predicted N terminal: His
Species:	Human
Expression Host:	E. coli
Accession:	Q9BPW9-1
Molecular Weight:	35.5 kDa (predicted); 34 kDa (reducing conditions)

QC Testing

Biological Activity:	Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first.
Purity:	> 90 % as determined by SDS-PAGE
Endotoxin:	Please contact us for more information.
Formulation:	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization.

Preparation and Storage

Reconstitution:

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

Stability & Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

Protein Background

Dehydrogenase/reductase (SDR family) member 9 (DHRS9) is aberrantly expressed in colorectal cancer (CRC), the decreased expression of DHRS9 correlates with tumor progression and may serve as a potential prognostic biomarker in CRC. The human regulatory macrophage (Mreg) has emerged as a promising cell type for use as a cell-based adjunct immunosuppressive therapy in solid organ transplant recipients. DHRS9 is a specific and stable

marker of human Mregs.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481